Spruce Biosciences, Inc.
SPRB
$55.11
$2.344.43%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 521.77% | -135.84% | |||
| Gross Profit | -521.77% | 135.84% | |||
| SG&A Expenses | -11.69% | 55.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 274.59% | -61.11% | |||
| Operating Income | -274.59% | 61.11% | |||
| Income Before Tax | 16.25% | -78.35% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 16.25% | -78.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 16.25% | -78.35% | |||
| EBIT | -274.59% | 61.11% | |||
| EBITDA | -267.29% | 61.16% | |||
| EPS Basic | 20.78% | 22.62% | |||
| Normalized Basic EPS | -71.99% | 64.36% | |||
| EPS Diluted | 20.78% | 22.62% | |||
| Normalized Diluted EPS | -71.99% | 64.36% | |||
| Average Basic Shares Outstanding | 5.73% | 130.47% | |||
| Average Diluted Shares Outstanding | 5.73% | 130.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||